29648-66-6

Usage

Uses

Used in the Food Industry:
4-Methylenecyclohexanone is used as a flavoring agent for its strong, floral odor, enhancing the taste and aroma of various food products.
Used in the Fragrance Industry:
4-Methylenecyclohexanone is used as a precursor in the synthesis of fragrances, contributing to the creation of various scent profiles in perfumes and other scented products.
Used in the Pharmaceutical Industry:
4-Methylenecyclohexanone is used as a precursor in the synthesis of pharmaceuticals, playing a crucial role in the development of different medicinal compounds.
Used in the Production of Piperonylmethyl Ketone:
4-Methylenecyclohexanone is a key intermediate in the production of piperonylmethyl ketone, which is utilized in the manufacture of amphetamine and methamphetamine. This highlights its importance in the chemical synthesis process for specific applications.
Safety Measures:
Due to its flammable nature, 4-Methylenecyclohexanone requires strict safety measures during handling to prevent fire and explosion hazards. Proper storage, handling, and usage protocols must be followed to ensure the safety of individuals and the environment.

Upstream product

• 22428-85-9 4-Methylencyclohexanol 
• 19740-31-9 spiro{2.4}heptan-5-one 
• 51656-90-7 8-methylene-1,4-dioxaspiro[4.5]decane 
• 13482-22-9 4-hydroxycyclohexanone 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 71435-94-4 <(4-Methoxy-1.4-cyclohexadien-1-yl)methyl>trimethylsilan 

Downstream Products

• 84215-13-4 4-Methylene-1-pent-4-enyl-cyclohexanol 
• 106434-97-3 4-Methylencyclohexanon-p-toluolsulfonohydrazon 
• 502870-59-9 1-(difluoromethylene)-4-methylenecyclohexane 
• 479638-02-3 4-methylene-1-trimethylsilyloxycyclohexene 
• 552840-04-7 (S)-[2,2-dimethyl-1-(trimethylsilyloxymethyl)propyl]-(4-methylenecyclohexylidene)amine 
• 479638-06-7 4,5,7,8-tetrahydro-3a,7-methanoazulene-2,6-dione 
• 84215-18-9 1-allyl-4-methylenecyclohexene 
• 84215-19-0 1-allylidene-4-methylenecyclohexene 
• 84237-45-6 1-propenyl-4-methylenecyclohexene 
• 84215-14-5 1-Methylene-4-pent-4-enylidene-cyclohexane 
• 84215-21-4 Acetic acid 1-allyl-4-methylene-cyclohexyl ester 
• 82353-67-1 4-Methylene-1-pent-4-enyl-cyclohexene 
• 861859-51-0 1-(3-tert-butyl-phenyl)-4-methylene-cyclohexanol 
• 1477524-76-7 1-(4-bromophenyl)-4-(iodomethyl)-7-oxabicyclo[2.2.1]heptane 

Relevant academic research and scientific papers

CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS

The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.

FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS

The present invention provides a compound of formula (I); a method for manufacturing the compounds of the invention, and its use as a IGF-1R inhibitor. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES

The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.

ETHER DERIVATIVES OF BICYCLIC HETEROARYLS

The invention relates to compounds of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; such compounds as a medicament; such compounds for the treatment of a proliferative disease

Design and synthesis of cell potent BACE-1 inhibitors: Structure-activity relationship of P1′ substituents

Using structure-guided design, hydroxyethylamine BACE-1 inhibitors were optimized to nanomolar Aβ cellular inhibition with selectivity against cathepsin-D. X-ray crystallography illuminated the S1′ residues critical to this effort, which culminated in compounds 56 and 57 that exhibited potency and selectivity but poor permeability and high P-gp efflux.

OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS

The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a colletion of diseases, disorders, and conditions associated with abnormal deposition of A-beta protei

OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS

The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS

The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS

The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and condition associated with abnormal deposition of A-beta protein.

SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS

The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.